Abcuro

Abcuro

Biotechnology, 90 Bridge St Ste 100, Newton, Massachusetts, 02458, United States, 1-10 Employees

abcuro.com

  • facebook
  • LinkedIn

phone no Phone Number: 61********

Who is ABCURO

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune check...

Read More

map
  • 90 Bridge St Ste 100, Newton, Massachusetts, 02458, United States Headquarters: 90 Bridge St Ste 100, Newton, Massachusetts, 02458, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 54 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ABCURO

Abcuro Org Chart and Mapping

Employees

Dave Borbas

VP Research, Head of Data Management

Michael McClain

Associate Director, Clinical Operations

Karen Tubridy

Chief Development Officer

Jorge Escobar

Vice President Clinical Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Abcuro

Answer: Abcuro's headquarters are located at 90 Bridge St Ste 100, Newton, Massachusetts, 02458, United States

Answer: Abcuro's phone number is 61********

Answer: Abcuro's official website is https://abcuro.com

Answer: Abcuro's revenue is $1 Million to $5 Million

Answer: Abcuro's SIC: 8731

Answer: Abcuro's NAICS: 54

Answer: Abcuro has 1-10 employees

Answer: Abcuro is in Biotechnology

Answer: Abcuro contact info: Phone number: 61******** Website: https://abcuro.com

Answer: Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access